CSF biomarkers predict a more malignant outcome in Alzheimer disease

Neurology

Volumn 74, Issue 19, 2010, Pages 1531-1537

  Wallin, A K ^a,b   Blennow, K ^c   Zetterberg, H ^c   Londos, E ^a,b   Minthon, L ^a,b   Hansson, O ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL TRIAL; CLUSTER ANALYSIS; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TAU PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952202260     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dd4dd8     Document Type: Article

References (33)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
2. McKhann G, Drachman DA, Folstein MF, Katzman R, Prince D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
3. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
4. Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuro-sci Lett 2007;419:18-22. (Pubitemid 46694097) (Pubitemid 46694097) (Pubitemid 46694097)
5. van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009;72:1056-1061.
6. Wallin ÅK, Andreasen N, Eriksson S, et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007;23:150-160.
7. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
9. Lawton MP, Brody EM. Assessments of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
10. Guy W. ECDEU Assessment Manual for Psychopharma-cology, Revised. Rockville, MD: US Department of Health Education and Welfare; 1976:218-220.
11. Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 1996;8:277-288.
12. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
13. Blennow K, Ricksten A, Prince JA, et al. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000;107:1065-1079.
14. Iqbal K, Flory M, Khatoon S, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005;58:748-757.
15. Engelborghs S, Maertens K, Vloeberghs E, et al. Neuropsychological and behavioural correlates of CSF biomark-ers in dementia. Neurochem Int 2006;48:286-295. (Pubitemid 43177150) (Pubitemid 43177150) (Pubitemid 43177150)
16. Wallin ÅK, Blennow K, Andreasen N, Minthon L. CSF-biomarkers for Alzheimer's disease-levels of/3-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21:131-138.
17. Stefani A, MartoranaA, Bernardini S, etal. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 2006;251:124-128.
18. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
19. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
20. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 1998;50:136-145.
21. Raskind MA, Peskind ER, Wessel T, Yuan W. Galan-tamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension: The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.
22. Farlow M, Anand R, Messina JJ, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241.
23. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276.
24. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009;66:638-645.
25. Sämgård K, Zetterberg H, Blennow K, Hansson O, Mint-hon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry Epub 2009 Aug 3.
26. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
27. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
28. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60:1495-1500.
29. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339:99-102.
30. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Win-blad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737-743.
31. Heyman A, Peterson B, Fillenbaum G, Pieper C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part XIV: demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology 1996;46:656-660.
32. Bowen JD, Malter AD, Sheppard L, et al. Predictors of mortality in patients diagnosed with probable Alzheimer's disease. Neurology 1996;47:433-439.
33. Combrinck M, Williams J, De Berardinis MA, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77:85-88.